{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T15:06:01Z","timestamp":1787583961979,"version":"build-2736575974"},"reference-count":81,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["AL200064"],"award-info":[{"award-number":["AL200064"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000971","name":"ALS Association","doi-asserted-by":"publisher","award":["20-IIA-431"],"award-info":[{"award-number":["20-IIA-431"]}],"id":[{"id":"10.13039\/100000971","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01NS120926, R01NS127188, F31NS139629"],"award-info":[{"award-number":["R01NS120926, R01NS127188, F31NS139629"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Amyotrophic lateral sclerosis (ALS) is a lethal neurodegenerative disease with few treatment options, rendering the development of new, effective therapeutics of critical importance. The immune system plays a substantial role in ALS pathology, with multiple cell populations implicated in disease progression. Natural killer (NK) cells are innate immune cells that accumulate in the brain and spinal cord during ALS, increasing neuroinflammation and killing motor neurons. Depleting NK cells extends survival in mouse models of ALS. Tofacitinib, an FDA-approved janus kinase (Jak) and signal transducer and activator (STAT) pathway inhibitor, reduces NK cytotoxicity and decreases overall levels in peripheral blood and may represent a potential ALS therapy. Therefore, we aimed to evaluate the effects of tofacitinib treatment on survival and phenotype in an ALS mouse model. Additionally, we sought to determine the impact of dose and regimen on efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      <jats:italic>SOD1<\/jats:italic>\n                      <jats:sup>G93A<\/jats:sup>\n                      mice, the most used rodent model of ALS, were treated with low- (5 mg\/kg) and high-dose (30 mg\/kg) tofacitinib following a prevention regimen, an intervention regimen, or a drug-cycling regimen, with survival being the primary outcome. Symptom onset was assessed via body weight, agility, and grip strength measurements. At end-stage disease (i) motor neurons and neuromuscular junctions were counted, (ii) immune populations were quantified via flow cytometry in peripheral blood and spinal cord, (iii) microglial surface marker expression was quantified to assess neuroinflammation, and (iv) bulk RNA-seq was performed on spinal cord.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Low-dose, but not high-dose, tofacitinib significantly increased survival and delayed weight loss. Notably, beginning treatment before symptom onset (prevention) did not offer any survival advantage over the intervention nor cycling regimen; further analyses were pooled by dose. There were no differences in motor neuron or neuromuscular junction counts. Peripheral NK and CD8+ T\u00a0cells\u00a0were decreased dose-dependently. Interestingly, spinal cord infiltrating NK\u00a0cells\u00a0increased with low-dose tofacitinib, though no other changes in neuroinflammation were observed. RNA-seq revealed that low-dose tofacitinib treatment reversed the dysregulation of multiple immune and metabolic pathways.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These data support the repurposing of tofacitinib as a potential ALS treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1662197","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T06:28:36Z","timestamp":1762324116000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Tofacitinib extends survival in a mouse model of ALS through NK cell-independent mechanisms"],"prefix":"10.3389","volume":"16","author":[{"given":"Lillia A.","family":"Baird","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel J.","family":"Teener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian F.","family":"Webber-Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D.","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dae-Gyu","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua P.","family":"Famie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline E.","family":"Piecuch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva L.","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin J.","family":"Murdock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01272-7","article-title":"Amyotrophic lateral sclerosis","volume":"400","author":"Feldman","year":"2022","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00465-8","article-title":"Recent advances in the diagnosis and prognosis of amyotrophic lateral sclerosis","volume":"21","author":"Goutman","year":"2022","journal-title":"Lancet Neurol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"fcaa124","DOI":"10.1093\/braincomms\/fcaa124","article-title":"Immunity in amyotrophic lateral sclerosis: Blurred lines between excessive inflammation and inefficient immune responses","volume":"2","author":"B\u00e9land","year":"2020","journal-title":"Brain Commun"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00279","article-title":"The peripheral immune system and amyotrophic lateral sclerosis","volume":"11","author":"McCombe","year":"2020","journal-title":"Front neurol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00414-2","article-title":"Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis","volume":"21","author":"Goutman","year":"2022","journal-title":"Lancet Neurol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200241","article-title":"Peripheral immune profiles predict ALS progression in an age-and sex-dependent manner","volume":"11","author":"Murdock","year":"2024","journal-title":"Neurol: Neuroimmunol Neuroinflammation"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.147129","article-title":"NK cells associate with ALS in a sex-and age-dependent manner","volume":"6","author":"Murdock","year":"2021","journal-title":"JCI Insight"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000242","article-title":"Increased ratio of circulating neutrophils to monocytes in amyotrophic lateral sclerosis","volume":"3","author":"Murdock","year":"2016","journal-title":"Neurol: Neuroimmunol Neuroinflammation"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2017.2255","article-title":"Correlation of peripheral immunity with rapid amyotrophic lateral sclerosis progression","volume":"74","author":"Murdock","year":"2017","journal-title":"JAMA neurol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000953","article-title":"Amyotrophic lateral sclerosis survival associates with neutrophils in a sex-specific manner","volume":"8","author":"Murdock","year":"2021","journal-title":"Neurol: Neuroimmunol Neuroinflammation"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0182002","article-title":"Comprehensive immune profiling reveals substantial immune system alterations in a subset of patients with amyotrophic lateral sclerosis","volume":"12","author":"Gustafson","year":"2017","journal-title":"PLoS One"},{"key":"B12","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/emmm.201201544","article-title":"Regulatory T-lymphocytes mediate amyotrophic lateral sclerosis progression and survival","volume":"5","author":"Henkel","year":"2013","journal-title":"EMBO Mol Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.89530","article-title":"ALS patients\u2019 regulatory T lymphocytes are dysfunctional, and correlate with disease progression rate and severity","volume":"2","author":"Beers","year":"2017","journal-title":"JCI Insight"},{"key":"B14","doi-asserted-by":"publisher","first-page":"fcaa152","DOI":"10.1093\/braincomms\/fcaa152","article-title":"Creatinine and C-reactive protein in amyotrophic lateral sclerosis, multiple sclerosis and Parkinson\u2019s disease","volume":"2","author":"Cui","year":"2020","journal-title":"Brain Commun"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.74065","article-title":"Correlation between leukocyte phenotypes and prognosis of amyotrophic lateral sclerosis","volume":"11","author":"Cui","year":"2022","journal-title":"Elife"},{"key":"B16","doi-asserted-by":"publisher","first-page":"6733","DOI":"10.1038\/s41467-022-34526-9","article-title":"T cell responses at diagnosis of amyotrophic lateral sclerosis predict disease progression","volume":"13","author":"Yazdani","year":"2022","journal-title":"Nat Commun"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25614","article-title":"Peripheral immune biomarkers and neurodegenerative diseases: a prospective cohort study with 20 years of follow-up","volume":"86","author":"Yazdani","year":"2019","journal-title":"Ann neurol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1038\/s41467-020-15644-8","article-title":"Natural killer cells modulate motor neuron-immune cell cross talk in models of Amyotrophic Lateral Sclerosis","volume":"11","author":"Garofalo","year":"2020","journal-title":"Nat Commun"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1242\/dmm.041947","article-title":"Temporal evolution of the microbiome, immune system and epigenome with disease progression in ALS mice","volume":"13","author":"Figueroa-Romero","year":"2019","journal-title":"Dis Models Mech"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0804610105","article-title":"T lymphocytes potentiate endogenous neuroprotective inflammation in a mouse model of ALS","volume":"105","author":"Chiu","year":"2008","journal-title":"Proc Natl Acad Sci"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0022374","article-title":"Abnormal changes in NKT cells, the IGF-1 axis, and liver pathology in an animal model of ALS","volume":"6","author":"Finkelstein","year":"2011","journal-title":"PLoS One"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0607423103","article-title":"Wild-type microglia extend survival in PU. 1 knockout mice with familial amyotrophic lateral sclerosis","volume":"103","author":"Beers","year":"2006","journal-title":"Proc Natl Acad Sci"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/glia.20919","article-title":"Extracellular mutant SOD1 induces microglial-mediated motoneuron injury","volume":"58","author":"Zhao","year":"2010","journal-title":"Glia"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awr074","article-title":"Endogenous regulatory T lymphocytes ameliorate amyotrophic lateral sclerosis in mice and correlate with disease progression in patients with amyotrophic lateral sclerosis","volume":"134","author":"Beers","year":"2011","journal-title":"Brain"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcn.2005.10.016","article-title":"The chemokine MCP-1 and the dendritic and myeloid cells it attracts are increased in the mSOD1 mouse model of ALS","volume":"31","author":"Henkel","year":"2006","journal-title":"Mol Cell Neurosci"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0807419105","article-title":"CD4+ T cells support glial neuroprotection, slow disease progression, and modify glial morphology in an animal model of inherited ALS","volume":"105","author":"Beers","year":"2008","journal-title":"Proc Natl Acad Sci"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1172\/JCI62636","article-title":"Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS","volume":"122","author":"Butovsky","year":"2012","journal-title":"J Clin Invest"},{"key":"B28","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/ana.20903","article-title":"Trial of celecoxib in amyotrophic lateral sclerosis","volume":"60","author":"Cudkowicz","year":"2006","journal-title":"Ann neurol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(07)70270-3","article-title":"Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial","volume":"6","author":"Gordon","year":"2007","journal-title":"Lancet Neurol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1212\/01.wnl.0000191326.40772.62","article-title":"Pentoxifylline in ALS: a double-blind, randomized, multicenter, placebo-controlled trial","volume":"66","author":"Meininger","year":"2006","journal-title":"Neurology"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3109\/17482960902803432","article-title":"Glatiramer acetate has no impact on disease progression in ALS at 40 mg\/day: a double-blind, randomized, multicentre, placebo-controlled trial","volume":"10","author":"Meininger","year":"2009","journal-title":"Amyotrophic Lateral Sclerosis"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2021.06.027","article-title":"Interplay between immunity and amyotrophic lateral sclerosis: Clinical impact","volume":"127","author":"De Marchi","year":"2021","journal-title":"Neurosci Biobehav Rev"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/ni1582","article-title":"Functions of natural killer cells","volume":"9","author":"Vivier","year":"2008","journal-title":"Nat Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.773288","article-title":"Tofacitinib suppresses natural killer cells in vitro and in vivo: implications for amyotrophic lateral sclerosis","volume":"13","author":"Figueroa-Romero","year":"2022","journal-title":"Front Immunol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-019-1964-1","article-title":"Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations","volume":"21","author":"McInnes","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1126\/science.8209258","article-title":"Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation","volume":"264","author":"Gurney","year":"1994","journal-title":"Science"},{"key":"B37","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.clim.2018.03.002","article-title":"Reversibility of peripheral blood leukocyte phenotypic and functional changes after exposure to and withdrawal from tofacitinib, a Janus kinase inhibitor, in healthy volunteers","volume":"191","author":"Weinhold","year":"2018","journal-title":"Clin Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1002\/art.40780","article-title":"Evaluation of the short-, mid-, and long-term effects of tofacitinib on lymphocytes in patients with rheumatoid arthritis","volume":"71","author":"van Vollenhoven","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1097\/TP.0b013e31818bbea7","article-title":"The effect of the JAK inhibitor CP-690,550 on peripheral immune parameters in stable kidney allograft patients","volume":"87","author":"van Gurp","year":"2009","journal-title":"Transplantation"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btu170","article-title":"Trimmomatic: a flexible trimmer for Illumina sequence data","volume":"30","author":"Bolger","year":"2014","journal-title":"Bioinformatics"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.3317","article-title":"HISAT: a fast spliced aligner with low memory requirements","volume":"12","author":"Kim","year":"2015","journal-title":"Nat Methods"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btt656","article-title":"featureCounts: an efficient general purpose program for assigning sequence reads to genomic features","volume":"30","author":"Liao","year":"2014","journal-title":"Bioinformatics"},{"key":"B43","doi-asserted-by":"publisher","first-page":"lqaa078","DOI":"10.1093\/nargab\/lqaa078","article-title":"ComBat-seq: batch effect adjustment for RNA-seq count data","volume":"2","author":"Zhang","year":"2020","journal-title":"NAR Genom Bioinform"},{"key":"B44","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.113.054940","article-title":"The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a janus kinase inhibitor, in humans","volume":"42","author":"Dowty","year":"2014","journal-title":"Drug Metab Disposition"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00438-4","article-title":"Current and future status of JAK inhibitors","volume":"398","author":"McLornan","year":"2021","journal-title":"Lancet"},{"key":"B47","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: from bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal transduction targeted Ther"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nbd.2015.02.017","article-title":"The dual roles of immunity in ALS: injury overrides protection","volume":"77","author":"Murdock","year":"2015","journal-title":"Neurobiol disease"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac710","article-title":"Janus kinase inhibitors alter NK cell phenotypes and inhibit their antitumour capacity","volume":"62","author":"Meudec","year":"2023","journal-title":"Rheumatology"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2011.03446.x","article-title":"CD11b and CD27 reflect distinct population and functional specialization in human natural killer cells","volume":"133","author":"Fu","year":"2011","journal-title":"Immunology"},{"key":"B51","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12974-025-03347-0","article-title":"Single-cell RNA sequencing highlights the role of distinct natural killer subsets in sporadic amyotrophic lateral sclerosis","volume":"22","author":"\u00c1lvarez-S\u00e1nchez","year":"2025","journal-title":"J Neuroinflammation"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2018.0035","article-title":"Association of regulatory T-cell expansion with progression of amyotrophic lateral sclerosis: a study of humans and a transgenic mouse model","volume":"75","author":"Sheean","year":"2018","journal-title":"JAMA neurol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"5941","DOI":"10.1038\/s41598-020-62756-8","article-title":"Peripheral proinflammatory Th1\/Th17 immune cell shift is linked to disease severity in amyotrophic lateral sclerosis","volume":"10","author":"Jin","year":"2020","journal-title":"Sci Rep"},{"key":"B54","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jcmgh.2021.09.004","article-title":"Tofacitinib-induced modulation of intestinal adaptive and innate immunity and factors driving cellular and systemic pharmacokinetics","volume":"13","author":"Texler","year":"2022","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0085463","article-title":"Fate of lymphocytes after withdrawal of tofacitinib treatment","volume":"9","author":"Piscianz","year":"2014","journal-title":"PLoS One"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-019-0320-3","article-title":"JAK inhibitors alter NK cell functions and may impair immunosurveillance against lymphomagenesis","volume":"17","author":"Nocturne","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-09-115030","article-title":"The specificity of JAK3 kinase inhibitors","volume":"111","author":"Changelian","year":"2008","journal-title":"Blood J Am Soc Hematol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001395","article-title":"Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme","volume":"6","author":"Cohen","year":"2020","journal-title":"RMD Open"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0000000000001608","article-title":"Effectiveness and safety of tofacitinib for ulcerative colitis: systematic review and meta-analysis","volume":"56","author":"Taneja","year":"2022","journal-title":"J Clin Gastroenterol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2015.06.060","article-title":"Aggression behaviour induced by oral administration of the Janus-kinase inhibitor tofacitinib, but not oclacitinib, under stressful conditions","volume":"764","author":"Fukuyama","year":"2015","journal-title":"Eur J Pharmacol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"5021537","DOI":"10.1155\/2016\/5021537","article-title":"Tolerogenic dendritic cells generated with tofacitinib ameliorate experimental autoimmune encephalomyelitis through modulation of Th17\/Treg balance","volume":"2016","author":"Zhou","year":"2016","journal-title":"J Immunol Res"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2011.12.156","article-title":"Low dose CP-690,550 (tofacitinib), a pan-JAK inhibitor, accelerates the onset of experimental autoimmune encephalomyelitis by potentiating Th17 differentiation","volume":"418","author":"Yoshida","year":"2012","journal-title":"Biochem Biophys Res Commun"},{"key":"B63","doi-asserted-by":"publisher","first-page":"102568","DOI":"10.1016\/j.msard.2020.102568","article-title":"CNS demyelination during tofacitinib therapy: first report","volume":"46","author":"Massoud","year":"2020","journal-title":"Multiple Sclerosis Related Disord"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2025.02.013","article-title":"Modifications on lipid profile and high-density lipoprotein function related to treatment with tofacitinib in female patients with rheumatoid arthritis: Impact of previous therapy with biological agents","author":"Botta","year":"2025","journal-title":"J Clin Lipidol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2017.06.012","article-title":"Effect of tofacitinib on lipid levels and lipid-related parameters in patients with moderate to severe psoriasis","volume":"11","author":"Wolk","year":"2017","journal-title":"J Clin lipidol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"13181","DOI":"10.3390\/ijms241713181","article-title":"Effects of tofacitinib on muscle remodeling in experimental rheumatoid sarcopenia","volume":"24","author":"Bermejo-\u00c1lvarez","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B67","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s42358-024-00416-5","article-title":"Treatment with tofacitinib attenuates muscle loss through myogenin activation in the collagen-induced arthritis","volume":"64","author":"da Rosa","year":"2024","journal-title":"Adv Rheumatol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdin.2024.11.009","article-title":"Weight gain secondary to the use of oral Janus kinase inhibitors: A systematic review and meta-analysis","author":"Xiong","year":"2024","journal-title":"JAAD Int"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-019-04303-x","article-title":"Dynamics of body mass index and visceral adiposity index in patients with rheumatoid arthritis treated with tofacitinib","volume":"39","author":"Novikova","year":"2019","journal-title":"Rheumatol Int"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1080\/17482960802295192","article-title":"High metabolic level in patients with familial amyotrophic lateral sclerosis","volume":"10","author":"Funalot","year":"2009","journal-title":"Amyotrophic Lateral Sclerosis"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-023-00845-8","article-title":"Nutritional and metabolic factors in amyotrophic lateral sclerosis","volume":"19","author":"Ludolph","year":"2023","journal-title":"Nat Rev Neurol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1002\/ana.27208","article-title":"Longitudinal metabolomics in amyotrophic lateral sclerosis implicates impaired lipid metabolism","author":"Guo","year":"2025","journal-title":"Ann Neurol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2007.03.066","article-title":"Lack of TDP-43 abnormalities in mutant SOD1 transgenic mice shows disparity with ALS","volume":"420","author":"Robertson","year":"2007","journal-title":"Neurosci letters"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21147","article-title":"Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations","volume":"61","author":"Mackenzie","year":"2007","journal-title":"Ann Neurol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1007\/s12031-017-0898-9","article-title":"Selection and prioritization of candidate drug targets for amyotrophic lateral sclerosis through a meta-analysis approach","volume":"61","author":"Morello","year":"2017","journal-title":"J Mol Neurosci"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202048922","article-title":"JAK inhibitors: Ten years after","volume":"51","author":"Spinelli","year":"2021","journal-title":"Eur J Immunol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"i4","DOI":"10.1093\/rheumatology\/key432","article-title":"Janus kinases to jakinibs: from basic insights to clinical practice","volume":"58","author":"Gadina","year":"2019","journal-title":"Rheumatology"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2021.1862084","article-title":"Interactions of janus kinase inhibitors with drug transporters and consequences for pharmacokinetics and toxicity","volume":"17","author":"Alim","year":"2021","journal-title":"Expert Opin Drug Metab toxicol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.738481","article-title":"Tofacitinib suppresses several JAK-STAT pathways in rheumatoid arthritis in vivo and baseline signaling profile associates with treatment response","volume":"12","author":"Palmroth","year":"2021","journal-title":"Front Immunol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-020-00938-z","article-title":"Critical assessment of pharmacokinetic drug\u2013drug interaction potential of tofacitinib, baricitinib and upadacitinib, the three approved janus kinase inhibitors for rheumatoid arthritis treatment","volume":"43","author":"Veeravalli","year":"2020","journal-title":"Drug safety"},{"key":"B81","doi-asserted-by":"publisher","first-page":"1756285617734734","DOI":"10.1177\/1756285617734734","article-title":"Disease-modifying and symptomatic treatment of amyotrophic lateral sclerosis","volume":"11","author":"Dorst","year":"2018","journal-title":"Ther Adv neurological Disord"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1662197\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T06:28:37Z","timestamp":1762324117000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1662197\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,5]]},"references-count":81,"alternative-id":["10.3389\/fimmu.2025.1662197"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1662197","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,5]]},"article-number":"1662197"}}